{"nctId":"NCT01718873","briefTitle":"Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer","startDateStruct":{"date":"2012-05","type":"ACTUAL"},"conditions":["Colorectal Cancer"],"count":230,"armGroups":[{"label":"bevacizumab before chemotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Bevacizumab","Drug: Oxaliplatin","Drug: levo-folinic acid","Drug: 5-fluorouracil","Drug: Capecitabine"]},{"label":"bevacizumab with chemotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab","Drug: Oxaliplatin","Drug: levo-folinic acid","Drug: 5-fluorouracil","Drug: Capecitabine"]}],"interventions":[{"name":"Bevacizumab","otherNames":["Avastin"]},{"name":"Oxaliplatin","otherNames":["Eloxatin"]},{"name":"levo-folinic acid","otherNames":["Lederfolin"]},{"name":"5-fluorouracil","otherNames":["Fluorouracil"]},{"name":"Capecitabine","otherNames":["Xeloda"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological diagnosis of colorectal adenoma carcinoma\n* Stage IV disease\n* Presence of at least one measurable target lesion (according to RECIST), and not previously radiated.\n* Age ≥ 18 e ≤ 75 years\n* ECOG Performance status 0-1\n* Life expectancy \\>3 months\n* Adequate recovery from surgery, with at least 28 days from surgery to date of pre-study biopsy.\n* Adequate contraception for male and female patients of child bearing potential\n* informed consent\n\nExclusion Criteria:\n\n* More than one previous line of therapy for metastatic disease\n* Prior treatment with bevacizumab or oxaliplatin (previous treatment with irinotecan,, cetuximab, fluoropyrimidine, folic acid are permitted)\n* Primary tumor that is stenosing and/or that infiltrates the entire thickness of the intestinal wall\n* Regular use of NSAIDs or aspirin\n* Bleeding disorders or coagulopathy\n* Concurrent anticoagulant therapy\n* Suspected or cerebral metastases (to verify in the presence of symptoms)\n* Neutrophils \\< 2000 / mm3, platelets \\< 100,000 / mm3, hemoglobin \\< 9g/dl\n* Creatinine \\> 1.5 times the upper normal limit\n* GOT and/or GPT \\> 2.5 times the upper normal limit, bilirubin \\> 1.5 times the upper normal limit in absence of liver metastases\n* GOT and/or GPT \\> 5 times the upper normal limit, bilirubin \\> 3 times the upper normal limit in presence of liver metastases\n* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal and squamous cell carcinoma or cervical cancer in situ\n* Congestive heart failure, ischemic coronary events within past 12 months, uncontrolled cardiac arrhythmia\n* Uncontrolled hypertension\n* Active or uncontrolled infection\n* Any concomitant condition that, in the investigator's opinion, would contraindicate the use of any of the study drugs\n* Pregnancy or lactation\n* Central nervous system disorders or peripheral neuropathy \\> grade 1 (CTCAE v. 4.0)\n* Inability to comply with follow up procedures of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate","description":"Objective response rate (ORR), according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, was the primary end point and was defined as the number of complete plus partial responses divided by the number of enrolled patients.\n\nPer RECIST v 1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"Disease control rate was calculated by adding complete and partial responses and stable disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time from randomization to the date of death. Patients alive at the time of the final analysis were censored on the date of the last follow-up information available.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival was defined as the time from randomization to the date of progression or death, whichever occurred first. Patients without progression were censored on the date of the last follow-up visit.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxic Effects","description":"Toxic effects were scored according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. For the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0 scale score range from 1 to 4. A high score, that is 3 and 4, represents a high level of toxicity, whereas the minimum values, that is 1 and 2, represents a mild/modest level of toxicity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":115},"commonTop":["Peripheral neuropathy","Nausea","Neutrophil count decreased","Diarrhea","White blood cell count decreased"]}}}